Erich Mounce: Biosimilars and the OCM

Erich Mounce, chief operating officer, OneOncology, discusses the role that biosimilars will have in practices meeting Oncology Care Model (OCM) goals.
December 04, 2019


Absolutely. I think so. I think that community oncology needs to embrace biosimilars. I think we have to make sure everybody's on the same page with how you consent patients for biosimilars. I think you have to understand what a biosimilar is, and that also is difficult for some practices to understand the interchangeability of that, but I absolutely think they can hit the goals. I absolutely think that biosimilars are going to transform the way we can participate in value-based contracts, whether it's OCM or a value-based contract with a payer.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.